All sponsors

Beijing Biostar Pharmaceuticals Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-32
RECRUITING1
READOUTS ≤12 MONTHS3
Open Beijing Biostar Pharmaceuticals Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Utidelone Capsule (Part 1)
NCT05700084
P1/2Active, not recruitingAdvanced Solid Tumor842025-10-08 (+24 mo)
Utidelone combined with Bevacizumab
NCT06683703
P2Not yet recruitingNon-small Cell Lung Cancer Patients with Brain Metastases1182026-12-01
Utidelone Capsule 60mg/m2/d
NCT06730581
P2Not yet recruitingGastric Cancer Adenocarcinoma Metastatic; Ovarian Cancer1002026-12-31
Utidelone capsule 75mg/m2/d QD
NCT07044349
P2Not yet recruitingOvarian Cancer; Fallopian Tube Cancer722027-03
Utidelone Capsule
NCT07684456
P3Not yet recruitingAdvanced Breast Cancer3082028-03-01
UTD2 + tislelizumab + doxorubicin
NCT07842276
P2Not yet recruitingSoft Tissue Sarcoma (STS); Utidelone492028-09-20
Utidelone Capsule
NCT06841679
P2/3RecruitingGastric or Gastroesophageal Junction Adenocarcinoma7782030-09-01